390 related articles for article (PubMed ID: 26945421)
61. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
[TBL] [Abstract][Full Text] [Related]
62. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
[TBL] [Abstract][Full Text] [Related]
63. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
[TBL] [Abstract][Full Text] [Related]
64. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
65. Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters.
Lee J; Kim SH; Kang BJ
Sci Rep; 2020 May; 10(1):7598. PubMed ID: 32371907
[TBL] [Abstract][Full Text] [Related]
66. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
Medicine (Baltimore); 2018 Jul; 97(30):e11647. PubMed ID: 30045313
[TBL] [Abstract][Full Text] [Related]
67. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement.
Kim SY; Cho N; Choi Y; Shin SU; Kim ES; Lee SH; Chang JM; Moon WK
Korean J Radiol; 2020 May; 21(5):561-571. PubMed ID: 32323501
[TBL] [Abstract][Full Text] [Related]
68. Kinetic Heterogeneity of Breast Cancer Determined Using Computer-aided Diagnosis of Preoperative MRI Scans: Relationship to Distant Metastasis-Free Survival.
Kim JY; Kim JJ; Hwangbo L; Suh HB; Kim S; Choo KS; Nam KJ; Kang T
Radiology; 2020 Jun; 295(3):517-526. PubMed ID: 32228293
[TBL] [Abstract][Full Text] [Related]
69. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
70. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
71. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
Wu S; Berg WA; Zuley ML; Kurland BF; Jankowitz RC; Nishikawa R; Gur D; Sumkin JH
Breast Cancer Res; 2016 Jul; 18(1):76. PubMed ID: 27449059
[TBL] [Abstract][Full Text] [Related]
72. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
Wu J; Gong G; Cui Y; Li R
J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
[TBL] [Abstract][Full Text] [Related]
73. Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?
Woolf DK; Padhani AR; Taylor NJ; Gogbashian A; Li SP; Beresford MJ; Ah-See ML; Stirling J; Collins DJ; Makris A
Breast Cancer Res Treat; 2014 Sep; 147(2):335-43. PubMed ID: 25129341
[TBL] [Abstract][Full Text] [Related]
74. Meta-Analysis of Quantitative Dynamic Contrast-Enhanced MRI for the Assessment of Neoadjuvant Chemotherapy in Breast Cancer.
Jun W; Cong W; Xianxin X; Daqing J
Am Surg; 2019 Jun; 85(6):645-653. PubMed ID: 31267907
[TBL] [Abstract][Full Text] [Related]
75. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
[TBL] [Abstract][Full Text] [Related]
76. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
77. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
[TBL] [Abstract][Full Text] [Related]
78. Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.
Christian N; Zabor EC; Cassidy M; Flynn J; Morrow M; Gemignani ML
Ann Surg Oncol; 2020 Mar; 27(3):743-749. PubMed ID: 31732944
[TBL] [Abstract][Full Text] [Related]
79. Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
Jochelson MS; Lampen-Sachar K; Gibbons G; Dang C; Lake D; Morris EA; Morrow M
Ann Surg Oncol; 2015 May; 22(5):1490-5. PubMed ID: 25777093
[TBL] [Abstract][Full Text] [Related]
80. Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center.
Sargent RE; Vazquez E; Kang I; Lu J; Manchandia T; Sheth P; Terando A; Nelson ME; Carr A; Hong DS; Sener SF
Am J Surg; 2022 Mar; 223(3):539-542. PubMed ID: 34801227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
